Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Trial Profile

Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Sialorrhoea
  • Focus Therapeutic Use
  • Acronyms Xeomin 2012
  • Most Recent Events

    • 27 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Jul 2012 Planned end date 1 Nov 2013 added as reported by ClinicalTrials.gov. (NCT01653132).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top